Peptides and proteins are made of the same thing: amino acids joined by peptide bonds. The difference is mainly size and what size brings with it. Peptides are short chains, usually up to about 40 or 50 amino acids, that are often flexible in solution; proteins are longer chains that fold into a stable three-dimensional structure. In US regulation the line is exact: the FDA defines a protein as a defined-sequence amino acid polymer of more than 40 amino acids.
That boundary is a convention rather than a change in chemistry, and a molecule of 35 or 60 residues can sit on either side depending on who is counting. This article sets out where the line is drawn, what actually differs on each side, and why the distinction matters for making, storing and analyzing these molecules in a laboratory.
What peptides and proteins have in common
Both are polymers of amino acids. Each amino acid contributes the same backbone unit (an amide nitrogen, an alpha carbon and a carbonyl carbon) plus a side chain, and the units are joined head to tail by peptide bonds. Both have an N-terminus and a C-terminus and are written from the first to the second. Both are made in cells on the ribosome from an mRNA template, and both are broken down by the same families of proteases.
The chemistry of the link is identical at every size. The planar, mostly trans peptide bond described in the article on the peptide bond behaves the same in a tripeptide and in a 1,000-residue enzyme. What changes as a chain grows is the number of ways it can interact with itself.
Amino acids, peptides, polypeptides and proteins
So what's the difference between a peptide and a protein in the plainest terms? Four words cover the whole scale:
- Amino acids are the individual building blocks. Different amino acids share one backbone and differ only in their side chains.
- Peptides are short chains of amino acids connected by peptide bonds. A dipeptide has two residues, a tripeptide three, and common usage runs from 2 to 50 amino acids.
- A polypeptide is a single long, unbranched chain. The word describes the chain without saying whether it has folded.
- Proteins are made from one or more long polypeptide chains that fold into complex three-dimensional structures. Proteins are typically larger, and it is the fold that allows a biological function such as catalysis or transport.
Peptides and proteins share the same chemical building blocks and the same bond, so the distinguishing factors are chain length and molecular structure, not composition. Structurally, the question to ask of any amino-acid chain is whether it can hold a fold by itself.
Peptides vs proteins at a glance
| Property | Peptides | Proteins |
|---|---|---|
| Typical length | 2 to about 40 or 50 residues | More than about 40 or 50 residues; usually 100 or more |
| US regulatory definition | 40 amino acids or fewer: not a "protein" under 21 CFR 600.3 | More than 40 amino acids with a defined sequence |
| Structure in water | Often flexible, with no single stable fold | Usually a defined tertiary fold; some have quaternary structure |
| Origin in cells | Usually cut from a larger precursor protein | Translated directly as the functional chain |
| Laboratory production | Chemical synthesis (solid-phase) | Recombinant expression in cells; small proteins by chemical ligation |
| Common identity tests | Intact mass by mass spectrometry, HPLC retention | Mass spectrometry, peptide mapping, electrophoresis |
| Main degradation routes | Hydrolysis, oxidation, deamidation | The same, plus unfolding and aggregation |
| Typical supply form | Lyophilized powder | Frozen solution or lyophilized with stabilizing additives |
Where the line is drawn
Scientific definitions
There is no single scientific cut-off. A 2021 review of short peptides in Molecules set the definitions side by side and found that they disagree. IUPAC treats chains under about 10 to 20 residues as oligopeptides and longer chains as polypeptides; other dictionaries extend oligopeptides to about 40 residues; and the review notes that typical proteins contain more than 100 amino acids. The authors proposed that short peptides should not exceed 45 amino acids, and they use "ultra-short" for peptides of up to seven.
In practice, many biochemists use about 50 residues as a working boundary, and they reserve "protein" for chains that fold on their own into a stable shape.
The FDA definition
US regulation needed a number, and it chose 40. Under 21 CFR 600.3(h)(6), a protein is "any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size." Chains that associate with each other as they do in nature are counted together, not separately.
The definition has practical consequences. On March 23, 2020, applications for a group of products that had historically been approved as drugs, insulins among them, were deemed to be biologics licenses under the PHS Act, moving them into the biological product framework. Insulin shows how the chain-counting rule works: its A chain has 21 residues and its B chain 30, joined by two interchain disulfide bonds, so it counts as 51 amino acids and is a protein under the definition even though neither chain alone exceeds 40.
A chain of 40 or fewer amino acids, by contrast, stays outside the definition. Most peptide hormones and their synthetic analogs fall on that side, including the GLP-1 receptor agonists discussed in GLP-1 receptor agonists: a research primer.
Size in perspective
Numbers help. The lengths below are the mature chains recorded in UniProt, the reference database for protein sequences.
| Molecule | Residues in the mature chain | Where it comes from |
|---|---|---|
| Met-enkephalin | 5 | Cut from pro-opiomelanocortin (POMC) |
| Arg-vasopressin | 9 | Cut from its precursor with neurophysin 2 |
| Alpha-MSH | 13 | Cut from POMC |
| Glucagon | 29 | Cut from proglucagon |
| Beta-endorphin | 31 | Cut from POMC |
| Amylin | 37 | Cut from its 89-residue precursor |
| Corticotropin (ACTH) | 39 | Cut from POMC |
| Insulin | 51 (21 + 30, two chains) | Cut from proinsulin |
| Ubiquitin | 76 | Released from polyubiquitin precursors |
| Hemoglobin alpha subunit | 141 | Translated directly |
| Growth hormone (somatotropin) | 191 | Translated directly |
| Serum albumin | 585 | Translated directly |
| Titin | 34,350 (canonical isoform) | Translated directly |
Everything from Met-enkephalin down to ACTH in the table is a peptide by any definition. Insulin and ubiquitin sit in the zone where the FDA calls them proteins and many researchers still call them small proteins or large peptides. From hemoglobin downward there is no ambiguity.
Structure: the real difference
Protein structure is described in four levels. The primary structure is the sequence. The secondary structure is local, regular folding of the backbone into alpha helices and beta strands, held by hydrogen bonds between peptide groups. The tertiary structure is the overall three-dimensional fold of one chain, and the quaternary structure is the way several chains pack together; hemoglobin, for example, is built from two alpha and two beta subunits.
A protein's function usually depends on its tertiary fold. An enzyme's active site, for example, brings together residues that are far apart in the sequence. That fold is held by many weak interactions (buried hydrophobic side chains, hydrogen bonds, salt bridges) and sometimes disulfide bonds, and it can be lost to heat, extreme pH or chemical denaturants.
Most short peptides never reach the tertiary level on their own. In water they sample a wide range of conformations, sometimes with a transient helix or turn, and many take a defined shape only when they bind a receptor, a membrane or a metal ion. Cyclic peptides and disulfide-bridged peptides such as oxytocin are the main exception: a ring removes much of the flexibility, which is one reason ring closure is a common strategy in peptide design.
This is why size and function track each other. Below a few dozen residues, a chain generally cannot bury enough hydrophobic surface to hold a stable fold. Above that, it can.
What peptides and proteins do
Biological roles divide roughly along the same line. Many peptides work as signals: a peptide hormone such as glucagon is released by one cell, binds a receptor on another, and changes the activities of other molecules inside it. The article on what peptides are covers peptide signaling in more detail.
Proteins take on the jobs that need a fixed shape. Enzymes, the receptors that peptides bind, transport proteins such as albumin and hemoglobin, and every antibody are proteins. So are structural materials. Type I collagen is a trimer of two alpha-1(I) chains and one alpha-2(I) chain, and the mature alpha-1(I) chain alone runs to 1,057 residues in UniProt. When proteases cut a protein like that into pieces, the pieces are peptides again, which is one more way the two categories turn into each other.
A peptide can live inside a protein
The line blurs further because many peptides start life as part of a protein. Proglucagon, a 180-residue precursor, is cut into glucagon, GLP-1, GLP-2 and other fragments depending on the tissue. POMC, 267 residues long, yields corticotropin, alpha-MSH, beta-endorphin and Met-enkephalin. Even hemoglobin's alpha subunit has a nine-residue stretch, hemopressin, that UniProt lists as a peptide in its own right.
In other words, "peptide" often describes a fragment's fate as much as its length: whether it is released and acts as a separate molecule, or stays part of a folded chain.
How each is made in the laboratory
Peptides are made chemically. In solid-phase peptide synthesis, the chain is built one residue at a time on a resin bead, then cleaved, deprotected and purified by reversed-phase HPLC. A figure of around 50 amino acids is often quoted as the practical limit for routine stepwise synthesis, but a 2016 review in the Journal of Peptide Science cautions that the number is close to meaningless, because many much shorter sequences are hard to make while some longer ones are straightforward.
That reach is why synthetic peptides are routine research tools: a defined amino-acid sequence can be specified, made and confirmed by mass, which is the basis of most peptide research.
Proteins are usually made biologically. The gene is expressed in bacteria, yeast, insect or mammalian cells, and the protein is purified from the cell culture. Expression gives access to chains of hundreds or thousands of residues, correct folding (in the right host) and some post-translational modifications.
Between the two sits chemical protein synthesis. In 1994, Dawson, Muir, Clark-Lewis and Kent described native chemical ligation, in which two unprotected peptide segments react through a thioester to give a native peptide bond at the join. It allowed a cytokine containing multiple disulfides to be made in one ligation step and then folded, and it is the standard way to make small proteins, or proteins carrying unnatural amino acids, by chemistry.
Handling and stability in the lab
The two classes degrade in overlapping but different ways.
Peptides are vulnerable to chemical changes along the chain: hydrolysis of the backbone (especially next to aspartic acid), oxidation of methionine, cysteine and tryptophan, and deamidation of asparagine and glutamine. Because a short peptide has little structure to lose, freeze-drying it rarely does harm, and a lyophilized peptide kept sealed, cold and dry can be stored for long periods. The article on how long peptides last covers shelf life in powder and in solution.
Proteins share all of those chemical risks and add physical ones. A folded protein can unfold, and unfolded chains can stick to each other and form aggregates. Freezing, thawing, agitation and air-water interfaces can all push a protein toward aggregation, so proteins are commonly handled in buffered solutions with additives chosen to protect the fold.
Anhydrolabs supplies only peptides, as lyophilized powder in vacuum-sealed vials and as 10-vial kits; copper-complexed GHK-Cu, a tripeptide, is one example from the catalog. All of it is research material for laboratory research use, as set out in research peptides.
Analyzing peptides and proteins
The analytical toolkit overlaps, but the emphasis differs. For a synthetic peptide, reversed-phase HPLC separates the target from deletion sequences and other synthesis by-products, and purity is reported as the area of the principal peak. Mass spectrometry confirms the intact mass, and tandem mass spectrometry can confirm the sequence. The article on peptide purity explains how the HPLC figure is produced.
For a protein, intact mass is still useful, but it is usually supplemented by peptide mapping (digesting the protein with a protease and analyzing the fragments), gel electrophoresis, and size-exclusion chromatography to detect aggregates, since a protein that is chemically intact can still be misfolded or clumped.
